Assessing the Impact of the NeuroCatch Platform 2 Stimulus Tone Volume

NCT04956172 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2022-03-24

No results posted yet for this study

Summary

The NeuroCatch Platform 2 (NCP2), an investigational medical device system developed by NeuroCatch Inc., consists of software and hardware that captures brain health information. The platform intends to provide a quick, portable and easy to use solution for the acquisition, display, analysis, storage, reporting and management of electroencephalograph (EEG) and event-related potential (ERP; brain response to a stimulus) information.

The NCP2 uses two types of tones to elicit N100 and P300 ERPs, along with two types of words to elicit N400 ERPs. The objective of this study is to determine if changing the volume of the standard tone has an effect on the amplitudes and latencies of the ERPs.

Conditions

  • Brain Health

Interventions

DEVICE

NeuroCatch Platform 2

To elicit the ERP components of interest in this study (N100, P300, N400), proprietary auditory stimulus sequences will be administered using the NeuroCatch Platform 2, an investigational medical device. Each sequence consists of tones and word pairs to elicit the various components of interest. The NeuroCatch Platform 2 consists of a computerized acquisition software which presents the stimulus, acquires the data and presents the amplitude and latency values of the ERP components (N100, N400, P300)

Sponsors & Collaborators

  • NeuroCatch Inc.

    lead INDUSTRY

Principal Investigators

  • Bimal Lakhani, PhD · NeuroCatch Inc.

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-07-12
Primary Completion
2021-08-31
Completion
2021-12-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04956172 on ClinicalTrials.gov